Hot Off the Presses: Roche is Hiring R&D Scientists???????
I was sitting around minding my own business (well sort of) and I received the following e-mail message. People must be reading BioJobBlog or something!
In the middle of the worst national job market since the early 1980's, Roche Pharma Research in Nutley, New Jersey is hiring. Specifically, this world class R&D center is seeking to hire 40 scientists to strengthen its research efforts to develop drugs to combat inflammatory diseases like arthritis and asthma.
In addition to Inflammation, Nutley continues to be the headquarters for Roche's Oncology Disease Biology Area, as well as RNA Therapeutics (an emerging area in understanding how genes are turned on and off in cells).
Focusing on drug discovery and non-clinical development, the site has a long tradition of discovering innovative new medicines.
Marcie Geremakis of Roche HR is available to discuss the efforts to recruit the new scientists and why Nutley is an outstanding environment for scientists. A number of scientists are available to discuss the following:
-
Roche's cutting edge scientific approaches to drug discovery focused on meeting the demands of the emerging need for personalized healthcare.
- Roche's intent to provide its scientists with the environment necessary to push forward novel ideas while challenging old paradigms.
- The ability to use state-of-the-art technology and collaborate with Roche's world class scientists across the globe engaged in biomarker discovery, novel biologics platforms, RNAi and diagnostics.
With well over 100 projects in research and more than 60 New Molecular Entities in development, Roche’s pipeline is among the best in the pharmaceuticals industry.
Please call me at 212-468-4306 or e-mail me at jillian.chertok@mslworldwide.com if you would like any additional information, or are interested in scheduling a time to speak with Marcie or one of the scientists at Roche.
I must disclose that I have no financial arrangement with this agency nor have I ever done business with them before. But, I figured if there are jobs to be had in this economy I ought to pass them on to folks who are looking.
Until next time...
Good Luck and Good Job Hunting!!!!!
Late Thursday, after 8 months of difficult and often acrimonious negotiations, Genentech’s board finally caved and agreed to allow Roche to purchase the remaining 44% of the outstanding Genentech shares that it doesn’t already own. The price: $95 per share—less than the $112 per share that Genentech’s board and management team wanted —but better than the $86.50 per share that was tendered last fall.
